205 related articles for article (PubMed ID: 36350851)
1. ATRX modulates the escape from a telomere crisis.
Geiller HEB; Harvey A; Jones RE; Grimstead JW; Cleal K; Hendrickson EA; Baird DM
PLoS Genet; 2022 Nov; 18(11):e1010485. PubMed ID: 36350851
[TBL] [Abstract][Full Text] [Related]
2. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).
Falcinelli M; Dell'Omo G; Grassi E; Mariella E; Leto SM; Scardellato S; Lorenzato A; Arena S; Bertotti A; Trusolino L; Bardelli A; d'Adda di Fagagna F
Cell Death Dis; 2023 Feb; 14(2):96. PubMed ID: 36759506
[TBL] [Abstract][Full Text] [Related]
4. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
[TBL] [Abstract][Full Text] [Related]
5. A non-genetic switch triggers alternative telomere lengthening and cellular immortalization in ATRX deficient cells.
Turkalo TK; Maffia A; Schabort JJ; Regalado SG; Bhakta M; Blanchette M; Spierings DCJ; Lansdorp PM; Hockemeyer D
Nat Commun; 2023 Feb; 14(1):939. PubMed ID: 36805596
[TBL] [Abstract][Full Text] [Related]
6. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
7. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
[TBL] [Abstract][Full Text] [Related]
8. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization.
Li F; Deng Z; Zhang L; Wu C; Jin Y; Hwang I; Vladimirova O; Xu L; Yang L; Lu B; Dheekollu J; Li JY; Feng H; Hu J; Vakoc CR; Ying H; Paik J; Lieberman PM; Zheng H
EMBO J; 2019 Oct; 38(19):e96659. PubMed ID: 31454099
[TBL] [Abstract][Full Text] [Related]
9. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
10. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
[TBL] [Abstract][Full Text] [Related]
11. Induction of the alternative lengthening of telomeres pathway by trapping of proteins on DNA.
Rose AM; Goncalves T; Cunniffe S; Geiller HEB; Kent T; Shepherd S; Ratnaweera M; O'Sullivan RJ; Gibbons RJ; Clynes D
Nucleic Acids Res; 2023 Jul; 51(13):6509-6527. PubMed ID: 36940725
[TBL] [Abstract][Full Text] [Related]
12. ATRX/DAXX: Guarding the Genome against the Hazards of ALT.
Clatterbuck Soper SF; Meltzer PS
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107548
[TBL] [Abstract][Full Text] [Related]
13. ATRX affects the repair of telomeric DSBs by promoting cohesion and a DAXX-dependent activity.
Lovejoy CA; Takai K; Huh MS; Picketts DJ; de Lange T
PLoS Biol; 2020 Jan; 18(1):e3000594. PubMed ID: 31895940
[TBL] [Abstract][Full Text] [Related]
14. The macroH2A1.2 histone variant links ATRX loss to alternative telomere lengthening.
Kim J; Sun C; Tran AD; Chin PJ; Ruiz PD; Wang K; Gibbons RJ; Gamble MJ; Liu Y; Oberdoerffer P
Nat Struct Mol Biol; 2019 Mar; 26(3):213-219. PubMed ID: 30833786
[TBL] [Abstract][Full Text] [Related]
15. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
16. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
[TBL] [Abstract][Full Text] [Related]
17. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
18. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
Mori JO; Keegan J; Flynn RL; Heaphy CM
J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
[TBL] [Abstract][Full Text] [Related]
19. Compromised Telomeric Heterochromatin Promotes ALTernative Lengthening of Telomeres.
Voon HPJ; Collas P; Wong LH
Trends Cancer; 2016 Mar; 2(3):114-116. PubMed ID: 28741530
[TBL] [Abstract][Full Text] [Related]
20. Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants.
Stundon JL; Ijaz H; Gaonkar KS; Kaufman RS; Jin R; Karras A; Vaksman Z; Kim J; Corbett RJ; Lueder MR; Miller DP; Guo Y; Santi M; Li M; Lopez G; Storm PB; Resnick AC; Waanders AJ; MacFarland SP; Stewart DR; Diskin SJ; Rokita JL; Cole KA
Neuro Oncol; 2023 Jul; 25(7):1331-1342. PubMed ID: 36541551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
